GSK, Moderna Settle COVID, RSV Patent Dispute
British drugmaker GSK and U.S. biotech firm Moderna announced a settlement of patent lawsuits concerning Moderna's COVID-19 vaccines Spikevax and mNEXSPIKE, as well as its RSV shot mResvia. The agreement, disclosed on Oct. 28, resolves GSK's infringement claims in both the United States and Europe and includes mutual cross-licensing of patents related to infectious disease technologies.
Under the terms, neither company is required to make any payments for the licenses. GSK highlighted that the resolution provides clarity and allows both firms to continue focusing on patient-focused innovation. The settlement also led Moderna to ask a Delaware federal court to dismiss GSK's US infringement claims with prejudice, preventing any future refiling.
The dispute stemmed from GSK's 2024 lawsuit alleging that Moderna's lipid nanoparticle delivery system for mRNA infringed its patents. GSK has a separate, still-pending case against Pfizer and BioNTech over similar technology.
Why it matters
The settlement removes a major legal uncertainty for insurers covering COVID-19 and RSV vaccine therapies.
FAQ
What patents were at issue in the GSK-Moderna dispute?
The lawsuits centered on GSK's patents covering lipid nanoparticle technology used to deliver mRNA in Moderna's vaccines.
Are any payments required under the settlement?
No, the cross-licenses were granted without any payment obligations.
Did the settlement affect GSK's lawsuit against Pfizer and BioNTech?
No, GSK's separate case against Pfizer and BioNTech remains ongoing.
Source: Insurance Journal. See the original source for full details.
Scan with your phone
Scan with your phone